Hematologic Malignancies

Top Story

Imetelstat demonstrates clinical activity for myelofibrosis, but may cause myelosuppression

September 2, 2015

The telomerase inhibitor imetelstat demonstrates clinical activity in patients with myelofibrosis, according to the results of a pilot study.

However, imetelstat (Geron Corporation) may potentially cause clinically significant myelosuppression, the researchers reported.

Susan M. O’Brien, MD In the Journals

Intensification of rituximab fails to benefit untreated patients with CLL

September 1, 2015
Additional doses of rituximab did not improve response rates among patients with chronic lymphocytic leukemia treated with the chemotherapy combination of fludarabine…
FDA News

FDA grants priority review to elotuzumab for multiple myeloma

September 1, 2015
The FDA granted priority review to elotuzumab for the treatment of patients with multiple myeloma who have received at least one prior therapy, according to a press…
In the Journals

Precision medicine techniques show promise for pediatric patients with relapsed, refractory cancer

September 1, 2015
The incorporation of integrative clinical sequencing data into the management of relapsed, refractory or rare cancers in children or young adults appeared feasible and…
CME
Hematology Oncology Case Consults

The Patient with Chronic Lymphocytic Leukemia

No commercial support for this activity.

This CME activity will focus on the diagnosis and management of patients with chronic lymphocytic leukemia.
More »
Meeting News Coverage Video
VIDEO: Surrogate endpoint for follicular lymphoma may hasten drug development

VIDEO: Surrogate endpoint for follicular lymphoma may hasten drug development

June 11, 2015
CHICAGO — Brian Bolwell, MD, chairman of the Taussig Cancer Institute of the Cleveland Clinic Foundation…
More »
CME
Hematology Oncology Case Consults

The Patient with Multiple Myeloma

No commercial support for this activity.

This CME activity will focus on the diagnosis and management of patients with multiple myeloma.
More »
In the Journals

Imetelstat demonstrates clinical activity for myelofibrosis, but may cause myelosuppression

September 2, 2015
The telomerase inhibitor imetelstat demonstrates clinical activity in patients with myelofibrosis, according to the results of a pilot study.However…
Susan M. O’Brien, MD In the Journals

Intensification of rituximab fails to benefit untreated patients with CLL

September 1, 2015
Additional doses of rituximab did not improve response rates among patients with chronic lymphocytic leukemia treated with the chemotherapy…
FDA News

FDA grants priority review to elotuzumab for multiple myeloma

September 1, 2015
The FDA granted priority review to elotuzumab for the treatment of patients with multiple myeloma who have received at least one prior therapy…
In the Journals

Precision medicine techniques show promise for pediatric patients with relapsed, refractory cancer

September 1, 2015
The incorporation of integrative clinical sequencing data into the management of relapsed, refractory or rare cancers in children or young adults…

Patients with RA may be at greater risk for developing lung cancer, lymphoma

August 31, 2015
Patients with rheumatoid arthritis may have a higher risk for developing lung cancer or lymphoma compared with the general population but may be at…
Mikkael A. Sekeres In the Journals

ED interventions reduce time to treatment of febrile neutropenia

August 31, 2015
The implementation of an intervention pathway reduced the time to administration of necessary antibiotics in the emergency department among adult…
Timothy J. Ley, MD In the Journals

Persistent mutations may predict EFS, OS outcomes in AML

August 28, 2015
Persistent leukemia-associated mutations in at least 5% of bone marrow cells in day 30 remission samples appeared to significantly increase the risk…
Noopur Raje, MD In the Journals

Daratumumab demonstrates single-agent activity in relapsed, refractory multiple myeloma

August 27, 2015
Daratumumab monotherapy appeared safe and effective for patients with heavily pretreated relapsed or refractory multiple myeloma, according to study…
In the Journals

Acute kidney injury, electrolyte abnormalities common among Ebola cases

August 25, 2015
Recently published data from an Ebola treatment center revealed a high prevalence of hematological and biochemical abnormalities among patients with…
John Sweetenham, MD EditorialPublication Exclusive

Research reveals fine line between ‘one more try’ and ‘a bridge too far’

HemOnc Today, August 25
John Sweetenham, MD
“I think we may be going a bridge too far.” – Lt. Gen. Frederick Browning, prior to the First Allied Airborne Army’s…
More Headlines »
morganatic-roan